Cellectar Biosciences, Inc.CLRBNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +247.84% | +115.80% | +57.02% | +851.95% | +141.16% |
| Weighted Average Shares Diluted Growth | +247.84% | +115.94% | +57.02% | +28.89% | +141.16% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +73.05% | +110.96% | -62.61% | -53.39% | -60.78% |
| Book Value per Share Growth | +0.00% | +0.00% | -62.14% | -94.30% | -74.35% |
| Debt Growth | -9.89% | -10.67% | -13.49% | -14.57% | -15.76% |
| R&D Expense Growth | -21.91% | -21.76% | -51.65% | -67.47% | -54.07% |
| SG&A Expenses Growth | +229.33% | +41.73% | -39.47% | -42.63% | -70.96% |